Tu1818 – Ultra-Proactive Therapeutic Drug Monitoring Incorporating Infliximab Point-Of-Care Testing with Ad Hoc Dose Adjustment Reduces C-Reactive Protein Levels in Patients with IBD During Infliximab Maintenance Treatment
2019 ◽
Vol 13
(Supplement_1)
◽
pp. S378-S378
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
2018 ◽
Vol 7
(1)
◽
2018 ◽
Vol 202
◽
pp. 1-12
◽
Keyword(s):